Application of apatinib in clinical treatment of advanced breast cancer

doi:10.3877/cma.j.issn.1674-0807.2023.01.001

Abstract

Abstract:

With the development of treatment strategies in recent years, the 5-year survival rate of early breast cancer patients is up to 90%. However, advanced breast cancer is almost incurable. Although effective chemotherapy, endocrine therapy and targeted therapy have improved the survival and prognosis of patients with advanced breast cancer, drug resistance and tumor progression are still inevitable. Angiogenesis is indispensable for tumor growth, invasion and metastasis. Anti-angiogenic drugs, which block neovascularization around tumors to inhibit tumor growth, have become key treatment of malignancy. Currently, none of the anti-angiogenic drugs applied in advanced breast cancer patients have shown significant clinical benefit for first-line treatment. In this paper, we reviewed the clinical efficacy and safety of apatinib alone or in combination with other anti-tumor agents in advanced breast cancer treatment, and summarized the results of researches on related biomarkers. Apatinib monotherapy for advanced metastatic breast cancer after the failure of multi-line therapy can achieve significant clinical efficacy with well-tolerated toxicity. The combination of apatinib with chemotherapy and immunotherapy also brings good outcome in refractory advanced patients.

Key words: Breast neoplasms, Angiogenesis inhibitors, Apatinib

Jiaxuan Liu, Maiyue He, Qiao Li, Binghe Xu. Application of apatinib in clinical treatment of advanced breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(01): 1-5.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2023.01.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2023/V17/I01/1

References 34

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021，71(3)：209-249.
[2]	Nair M, Sandhu SS, Sharma AK. Cancer molecular markers: a guide to cancer detection and management[J]. Semin Cancer Biol, 2018, 52(Pt 1): 39-55.
[3]	Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7): 747-758.
[4]	Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors[J]. Nat Rev Cancer, 2002, 2(10): 727-739.
[5]	Folkman J. Angiogenesis: an organizing principle for drug discovery？[J]. Nat Rev Drug Discov, 2007, 6(4): 273-286.
[6]	杨军，陈明清，董坚. VEGF/VEGFR2信号转导通路在抗肿瘤血管生成中的作用[J]. 世界华人消化杂志，2007，15(34): 3611-3616.
[7]	Siemann DW, Chaplin DJ, Horsman MR. Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer[J]. Cancer Invest, 2017, 35(8): 519-534.
[8]	Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci, 2011, 102(7): 1374-1380.
[9]	Zhang H, Sun J, Ju W, et al. Apatinib suppresses breast cancer cells proliferation and invasion via angiomotin inhibition[J]. Am J Transl Res, 2019，11(7)：4460-4469.
[10]	Maroufi NF, Vahedian V, Akbarzadeh M, et al. The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways[J]. Breast Cancer, 2020, 27(4): 613-620.
[11]	Jiang B, Zhu H, Tang L, et al. Apatinib inhibits stem properties and malignant biological behaviors of breast cancer stem cells by blocking Wnt/β-catenin signal pathway through down-regulating LncRNA ROR[J]. Anticancer Agents Med Chem, 2022，22(9)：1723-1734.
[12]	Maroufi NF, Rashidi M, Vahedian V, et al. Effect of apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line[J]. Breast Cancer, 2022, 29(2): 260-273.
[13]	Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J]. Int J Cancer, 2014, 135(8): 1961-1969.
[14]	Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14(1): 820.
[15]	Lin Y, Wu Z, Zhang J, et al. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment[J]. Tumour Biol, 2017, 39(6): 1010428317711033.
[16]	律慧敏，张梦玮，牛李敏，等. 甲磺酸阿帕替尼单药治疗多药耐药晚期乳腺癌临床观察[J]. 中华医学杂志，2018，98 (16): 1246-1249.
[17]	Li H, Geng C, Zhao H, et al. Multicenter phase Ⅱ study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis[J]. Chin J Cancer Res, 2021, 33(2): 243-255.
[18]	Gao Z, Shi M, Wang Y, et al. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2[J]. Pathol Res Pract, 2019, 215(7): 152 422.
[19]	Chen J, Deng S, Zhang Y, et al. Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer[J]. Ann Transl Med, 2021, 9(12): 1001.
[20]	Tang D, Ma J, Chu Z, et al. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin[J]. Am J Transl Res, 2020, 12(7): 3741-3753.
[21]	Zhu A, Yuan P, Wang J, et al. Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: an observational study[J]. Oncol Lett, 2019, 17(6): 4768-4778.
[22]	Liu Z, Shan J, Yu Q, et al. Real-world data on apatinib efficacy - results of a retrospective study in metastatic breast cancer patients pretreated with multiline treatment[J]. Front Oncol, 2021, 11: 643 654.
[23]	Li YH, Zhou Y, Wang YW, et al. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study[J]. Medicine (Baltimore), 2018, 97(36): e12222.
[24]	Chen J, Feng L, Sheng Q, et al. Efficacy, safety, and tumor marker inhibition of apatinib combined with conventional chemotherapy regimens for patients with advanced triple-negative breast cancer[J]. Evid Based Complement Alternat Med, 2021, 2021: 8720679.
[25]	Hu N, Zhu A, Si Y, et al. A phase Ⅱ，single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer[J]. Front Oncol, 2020, 10: 565 384.
[26]	Zhu A, Yuan P, Hu N, et al. Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA[J]. Cancer Biol Med, 2021, 18(3): 875-887.
[27]	Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study[J]. JAMA Oncol, 2019, 5(1): 74-82.
[28]	Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study[J]. J Clin Oncol, 2016, 34(21): 2460-2467.
[29]	Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study[J]. Breast Cancer Res Treat, 2018, 167(3): 671-686.
[30]	Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59.
[31]	Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade[J]. Sci Transl Med, 2017, 9(385)：eaak9670.
[32]	Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase Ⅱ trial[J]. J Immunother Cancer, 2020, 8(1)：e000696.
[33]	Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy[J]. Breast Cancer Res Treat, 2014, 143(1): 141-151.
[34]	Liu J, Li Y, Li Q, et al. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase Ⅱ trial in advanced triple-negative breast cancer patients[J]. Breast Cancer Res Treat, 2021, 186(3): 687-697.

Please choose a citation manager

Content to export